Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Evolysse Smooth is an FDA-approved, sterile, bioabsorbable injectable gel implant designed for the correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds, in adults aged 22 years and older. It contains 20 mg/mL crosslinked hyaluronic acid (HA) produced by Streptococcus species bacteria and 3 mg/mL lidocaine hydrochloride in a physiologic buffer. The HA is crosslinked with 1,4-butanediol diglycidyl ether (BDDE), enhancing its longevity and integration into the skin. The product utilizes Cold-X technology to better preserve the natural structure of HA for long-lasting, natural-looking results. Lidocaine is included to reduce pain during injection. Clinical studies demonstrated that Evolysse Smooth effectively reduces wrinkle severity with results lasting up to 12 months in most patients[1][5][6][9]. It is injected into the superficial-to-mid dermis and has a soft, highly spreadable gel texture suitable for fine lines and superficial volume loss[7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Evolysse Smooth.